FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028599473> ?p ?o ?g. }

• W3028599473 abstract "Although oncolytic viruses have shown clinical efficacy for local treatment of cancerous tumors, the ability to induce immune-mediated regression to visceral lesions is not robust. Immune checkpoint modulation has been efficacious in a fraction of cancers associated with an inflamed microenvironment but is associated with toxicity due to nonspecific T-cell activation. Therefore, combining these two strategies has the exciting potential to be an effective cancer therapy. Oncolytic virus can be genetically modified to decrease pathogenicity to normal cells and to increase their lytic potential and ability to stimulate antitumor immunity, thus improving the risk-benefit ratio for cancer patients. Oncorus oHSV (ONCR) are novel oncolytic herpes simplex virus type-1 vectors developed for the treatment of solid tumors. ONCR utilizes a unique conditional-lethal strategy in which tissue-specific miRs binding sites are inserted into early genes essential for viral replication and in the neurovirulence gene ICP34.5. This strategy curtails viral replication in normal cells, including neurons, and limits the expression of g34.5 to tumor cells, thus promoting potent viral replication in presence of type I interferon. Fifteen immunostimulatory transgenes and combination thereof were systematically evaluated in dual flank syngeneic mouse tumor models to test both for oncolysis and abscopal efficacy on the contralateral noninjected tumor. Among the selected transgenes, IL-12 was found to elicit the most potent efficacy on the ipsilateral and contralateral tumors. We demonstrated that the replication of ONCR and the expression of IL-12 was limited to the injected tumors. By contrast, induction of systemic immunity as assessed by IFNg production in contralateral tumors and in plasma was observed. ONCR expressing IL-12 elicited efficacy in multiple subcutaneous and metastatic models. Additional payloads designed to stimulate antigen presentation, recruitment of immune cells and inhibition of tumor immune suppression were identified as further enhancing IL-12 activity. Data supporting the selection of a suite of payloads cloned into a single ONCR vector will be presented. ONCR represents a new class of oncolytic virus that promote antitumor responses through a multiprong mechanism of action dependent on selective tumor cell killing, the induction of systemic antitumor immunity and reversion of immune suppression. Citation Format: Lorena Lerner, Edward M. Kennedy, Terry Farkaly, Allison Colthart, Caity Montagna, Prajna Behera, Judith Jacques, Peter Grzesik, Jennifer Lee, Agnieszka Denslow, Jacqueline Gursha, Brian Haines, Michael Ball, Daniel Wambua, Cecilia Kwong, Lingxin Kong, Michael Paglia, Laura Viggiano Salta, Lorenz Ponce, Caroline Webb, Mitchell Finer, Christophe Queva. microRNA attenuated oHSV-1 armed with multiple immunomodulatory payloads mediates robust and selective antitumor immune response in preclinical tumor models [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B23." @default.
• W3028599473 created "2020-06-05" @default.
• W3028599473 creator A5001372205 @default.
• W3028599473 creator A5004101885 @default.
• W3028599473 creator A5012348306 @default.
• W3028599473 creator A5014345315 @default.
• W3028599473 creator A5022201090 @default.
• W3028599473 creator A5023147612 @default.
• W3028599473 creator A5023270352 @default.
• W3028599473 creator A5027719354 @default.
• W3028599473 creator A5039193823 @default.
• W3028599473 creator A5041318859 @default.
• W3028599473 creator A5053570050 @default.
• W3028599473 creator A5060476958 @default.
• W3028599473 creator A5064187293 @default.
• W3028599473 creator A5064935817 @default.
• W3028599473 creator A5066193913 @default.
• W3028599473 creator A5067308803 @default.
• W3028599473 creator A5071036396 @default.
• W3028599473 creator A5071424437 @default.
• W3028599473 creator A5073917612 @default.
• W3028599473 creator A5074516218 @default.
• W3028599473 creator A5077215471 @default.
• W3028599473 creator A5086936630 @default.
• W3028599473 date "2020-04-01" @default.
• W3028599473 modified "2023-09-26" @default.
• W3028599473 title "Abstract B23: microRNA attenuated oHSV-1 armed with multiple immunomodulatory payloads mediates robust and selective antitumor immune response in preclinical tumor models" @default.
• W3028599473 doi "https://doi.org/10.1158/2326-6074.tumimm18-b23" @default.
• W3028599473 hasPublicationYear "2020" @default.
• W3028599473 type Work @default.
• W3028599473 sameAs 3028599473 @default.
• W3028599473 citedByCount "0" @default.
• W3028599473 crossrefType "proceedings-article" @default.
• W3028599473 hasAuthorship W3028599473A5001372205 @default.
• W3028599473 hasAuthorship W3028599473A5004101885 @default.
• W3028599473 hasAuthorship W3028599473A5012348306 @default.
• W3028599473 hasAuthorship W3028599473A5014345315 @default.
• W3028599473 hasAuthorship W3028599473A5022201090 @default.
• W3028599473 hasAuthorship W3028599473A5023147612 @default.
• W3028599473 hasAuthorship W3028599473A5023270352 @default.
• W3028599473 hasAuthorship W3028599473A5027719354 @default.
• W3028599473 hasAuthorship W3028599473A5039193823 @default.
• W3028599473 hasAuthorship W3028599473A5041318859 @default.
• W3028599473 hasAuthorship W3028599473A5053570050 @default.
• W3028599473 hasAuthorship W3028599473A5060476958 @default.
• W3028599473 hasAuthorship W3028599473A5064187293 @default.
• W3028599473 hasAuthorship W3028599473A5064935817 @default.
• W3028599473 hasAuthorship W3028599473A5066193913 @default.
• W3028599473 hasAuthorship W3028599473A5067308803 @default.
• W3028599473 hasAuthorship W3028599473A5071036396 @default.
• W3028599473 hasAuthorship W3028599473A5071424437 @default.
• W3028599473 hasAuthorship W3028599473A5073917612 @default.
• W3028599473 hasAuthorship W3028599473A5074516218 @default.
• W3028599473 hasAuthorship W3028599473A5077215471 @default.
• W3028599473 hasAuthorship W3028599473A5086936630 @default.
• W3028599473 hasConcept C104317684 @default.
• W3028599473 hasConcept C111599444 @default.
• W3028599473 hasConcept C121608353 @default.
• W3028599473 hasConcept C126322002 @default.
• W3028599473 hasConcept C140704245 @default.
• W3028599473 hasConcept C182615771 @default.
• W3028599473 hasConcept C19106626 @default.
• W3028599473 hasConcept C203014093 @default.
• W3028599473 hasConcept C2522874641 @default.
• W3028599473 hasConcept C2776107976 @default.
• W3028599473 hasConcept C2777283488 @default.
• W3028599473 hasConcept C2777701055 @default.
• W3028599473 hasConcept C2781196997 @default.
• W3028599473 hasConcept C32470452 @default.
• W3028599473 hasConcept C40767141 @default.
• W3028599473 hasConcept C502942594 @default.
• W3028599473 hasConcept C55493867 @default.
• W3028599473 hasConcept C71924100 @default.
• W3028599473 hasConcept C82210918 @default.
• W3028599473 hasConcept C86803240 @default.
• W3028599473 hasConcept C8891405 @default.
• W3028599473 hasConceptScore W3028599473C104317684 @default.
• W3028599473 hasConceptScore W3028599473C111599444 @default.
• W3028599473 hasConceptScore W3028599473C121608353 @default.
• W3028599473 hasConceptScore W3028599473C126322002 @default.
• W3028599473 hasConceptScore W3028599473C140704245 @default.
• W3028599473 hasConceptScore W3028599473C182615771 @default.
• W3028599473 hasConceptScore W3028599473C19106626 @default.
• W3028599473 hasConceptScore W3028599473C203014093 @default.
• W3028599473 hasConceptScore W3028599473C2522874641 @default.
• W3028599473 hasConceptScore W3028599473C2776107976 @default.
• W3028599473 hasConceptScore W3028599473C2777283488 @default.
• W3028599473 hasConceptScore W3028599473C2777701055 @default.
• W3028599473 hasConceptScore W3028599473C2781196997 @default.
• W3028599473 hasConceptScore W3028599473C32470452 @default.
• W3028599473 hasConceptScore W3028599473C40767141 @default.
• W3028599473 hasConceptScore W3028599473C502942594 @default.
• W3028599473 hasConceptScore W3028599473C55493867 @default.
• W3028599473 hasConceptScore W3028599473C71924100 @default.
• W3028599473 hasConceptScore W3028599473C82210918 @default.
• W3028599473 hasConceptScore W3028599473C86803240 @default.
• W3028599473 hasConceptScore W3028599473C8891405 @default.
• W3028599473 hasLocation W30285994731 @default.
• W3028599473 hasOpenAccess W3028599473 @default.
• W3028599473 hasPrimaryLocation W30285994731 @default.

• next